Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were col...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Yukinori, Tsurutani, Junji, Mukohara, Toru, Iwasa, Tsutomu, Takahashi, Masato, Tanabe, Yuko, Kawabata, Hidetaka, Masuda, Norikazu, Futamura, Manabu, Minami, Hironobu, Matsumoto, Koji, Yoshimura, Kenichi, Kitano, Shigehisa, Takano, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475259/
https://www.ncbi.nlm.nih.gov/pubmed/36118297
http://dx.doi.org/10.1016/j.dib.2022.108558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475259/
https://www.ncbi.nlm.nih.gov/pubmed/36118297
http://dx.doi.org/10.1016/j.dib.2022.108558

Ejemplares similares